Comparison · NCT03087019-deaths
Pembrolizumab + Radiation vs Pembrolizumab: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pembrolizumab + Radiation vs Pembrolizumab: deaths from any cause. Trial comparisons, record NCT03087019-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03087019-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.1 | 0.0179 | 0.404 | wilson | |
| Risk in group 2 | 0.1 | 0.0179 | 0.404 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.315 | 0.315 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.0721 | 13.9 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.0538 | 18.6 | log | |
| Number needed to harm | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pembrolizumab + Radiation | * Up to 5 metastatic lesions targeted with radiation~* Over 5 fractions starting within 7 calendar days following the first dose of pembrolizumab~* Pembrolizumab will be administered on day 1 of each 21day cycle~* Pembrolizumab is delivered intravenously~Radiation: Standard use of radiation is administered~Pembrolizumab: Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells. | 1 | 10 | EG000 |
| Group 2 | Pembrolizumab | * Pembrolizumab will be administered on day 1 of each 21day cycle~* Pembrolizumab is delivered intravenously~Pembrolizumab: Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells. | 1 | 10 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- 2 years
Source ClinicalTrials.gov
Trial
- Title
- Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
- NCT number
- NCT03087019
- Phases
- PHASE2
- Conditions
- Adenoid Cystic Carcinoma
- Interventions
- Radiation, Pembrolizumab
- Lead sponsor
- Dana-Farber Cancer Institute
- Results first posted
- 2021-04-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03087019?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03087019-deaths